Starting July 1, 2026 eligible Medicare enrollees will be able to access GLP-1 weight loss medications including Wegovy, Zepbound, and the newer drug Foundayo for a flat $50 monthly copay, in a historic first for the program, which has never before covered anti-obesity medications despite covering many of the serious
